Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Maki Gouda"'
Publikováno v:
Journal of Diabetes Investigation, Vol 13, Iss 11, Pp 1842-1851 (2022)
Abstract Aims/Introduction This study aimed to investigate the effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on new prescriptions of drugs, including antihypertensives, antigout/antihyperuricemics and antidyslipidemics, for the trea
Externí odkaz:
https://doaj.org/article/b96ca72883de42e1bc744792ef738e5a
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 11, Pp 2036-2045 (2021)
ABSTRACT Aims/Introduction The relationship between glycated hemoglobin (HbA1c) and cardiovascular events in older adults was investigated using a Japanese administrative medical database. Materials and Methods Anonymized medical data on patients wit
Externí odkaz:
https://doaj.org/article/c185fb53870a4386a0e351ed1615586a
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 11, Pp 2036-2045 (2021)
Journal of Diabetes Investigation
Journal of Diabetes Investigation
Aims/Introduction The relationship between glycated hemoglobin (HbA1c) and cardiovascular events in older adults was investigated using a Japanese administrative medical database. Materials and Methods Anonymized medical data on patients with diabete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a6335c8af6aee7f0d2b87138f8d377c
https://doaj.org/article/c185fb53870a4386a0e351ed1615586a
https://doaj.org/article/c185fb53870a4386a0e351ed1615586a
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Maki Gouda,1 Miyuki Matsukawa,2 Hiroaki Iijima3 1Medical Intelligence Department, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan; 2Data Science Department, Ikuyaku. Integrated Value Development Divi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4c33a3614904901d03c72b5209bca82
http://europepmc.org/articles/PMC6199223
http://europepmc.org/articles/PMC6199223
Autor:
Takashi Kadowaki, Nobuya Inagaki, Nobuko Maruyama, Yumi Watanabe, Nobuhiro Nakanishi, Kenichi Nishimura, Kazuoki Kondo, Hiroaki Iijima, Maki Gouda, Genki Kaneko
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To investigate efficacy and safety of the sodium–glucose co-transporter 2 (SGLT2) inhibitor canagliflozin administered as add-on therapy to the dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin in patients with type 2 diabetes mellitus (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a96cff7ab28da3253dbdf5da6bb425
http://europepmc.org/articles/PMC5484989
http://europepmc.org/articles/PMC5484989
Publikováno v:
Drugs
Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8d59a596ba926ca12379279087dccc4
https://pubmed.ncbi.nlm.nih.gov/30982160
https://pubmed.ncbi.nlm.nih.gov/30982160
Publikováno v:
Diabetes Technology & Therapeutics
Background: Albuminuria characterizes the progression of kidney injury. The effect of canagliflozin on the excretion of microalbumin was assessed for investigating its renoprotective potential in Japanese patients with type 2 diabetes mellitus (T2DM)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56aee343e128a04dc8315114178c53a5
https://pubmed.ncbi.nlm.nih.gov/30096243
https://pubmed.ncbi.nlm.nih.gov/30096243
Autor:
Nobuko Maruyama, Kazuoki Kondo, Maki Gouda, Hiroaki Iijima, Nobuhiro Nakanishi, Nobuya Inagaki, Genki Kaneko, Kenichi Nishimura, Yumi Watanabe, Takashi Kadowaki
Publikováno v:
Diabetes, Obesity & Metabolism
Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are frequently used in combination for the treatment of type 2 diabetes mellitus (T2DM). We examined the efficacy and safety of teneligliptin (a DPP-4 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c260237eac5709a471b6f0ecfbc9a510
https://pubmed.ncbi.nlm.nih.gov/28786530
https://pubmed.ncbi.nlm.nih.gov/28786530
Autor:
Genki Kaneko, Nobuhiro Nakanishi, Hiroaki Iijima, Kazuoki Kondo, Nobuya Inagaki, Yumi Watanabe, Maki Gouda, Nobuko Maruyama, Kenichi Nishimura, Takashi Kadowaki
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the long‐term safety and efficacy of canagliflozin as add‐on therapy in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycaemic control with teneligliptin monotherapy. Methods This open‐label 52‐week study w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3283f2c1cb898ad083239f3b5c1611b3
https://pubmed.ncbi.nlm.nih.gov/28608617
https://pubmed.ncbi.nlm.nih.gov/28608617
Autor:
Ryuji Terata, Shoko Yokota, Kyoko Miyayama, Noriyuki Sasaki, Maki Gouda, Takashi Kadowaki, Kazuoki Kondo
To assess the efficacy and safety of teneligliptin as add-on to insulin monotherapy in patients with type 2 diabetes mellitus (T2DM).In a 16-week, double-blind period, 148 Japanese T2DM patients with inadequate glycemic control with insulin and diet/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8754d4800a3cf9c6d0830428a4d82a2
